Literature DB >> 8619206

Surgical treatment strategy for patients with stage IV hepatocellular carcinoma.

M Shimada1, K Takenaka, N Kawahara, K Kajiyama, K Yamamoto, K Shirabe, T Nishizaki, K Yanaga, K Sugimachi.   

Abstract

BACKGROUND: This study was conducted to identify the prognostic indicators for patients with stage IV hepatocellular carcinoma (HCC), as well as to clarify the strategy of surgical treatment for those patients.
METHODS: Forty-six patients with stage IV HCC were included in this study. Prognostic factors were univariately and multivariately analyzed. Furthermore, the significance of intraoperative treatment for residual tumors was investigated in patients with an absolute noncurative operation.
RESULTS: The poor prognostic factors were as follows: host factors, Child's classification of B and C and immunosuppressive acidic protein level of greater than 400 micrograms/ml; tumor factors, tumor diameter of greater than 5 cm, poorly differentiated histologic features, positive portal vein invasion, and intrahepatic metastases involving more than three segments; others, an absolute noncurative operation and no preoperative treatment. Tumor diameter of more than 5 cm was then suggested to be an independent prognostic indicator. Survival of patients with stage IV-A HCC who underwent a curative operation was similar to that of those with stages III HCC: Furthermore, the survival of patients with Stage IV-A who had an absolute noncurative operation but underwent either intraoperative microwave coagulation or ethanol injection to the residual HCCs was not statistically different from that of those with a curative operation.
CONCLUSIONS: Therefore for stage IV-A HCC surgical treatment is considered to be both useful and the first choice of treatment when all the tumors in the liver can be removed or when the residual tumors can be treated during operation by either microwave coagulation or ethanol injection as a result of an incomplete removal of the tumors.

Entities:  

Mesh:

Year:  1996        PMID: 8619206     DOI: 10.1016/s0039-6060(96)80260-1

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus.

Authors:  M Minagawa; M Makuuchi; T Takayama; K Ohtomo
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Surgical treatment of hepatocellular carcinoma in China: surgical techniques, indications, and outcomes.

Authors:  Xiao-Ping Chen; Zhi-Yong Huang
Journal:  Langenbecks Arch Surg       Date:  2005-05-04       Impact factor: 3.445

3.  Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification.

Authors:  Ronnie Tung-Ping Poon; Sheung Tat Fan; Irene Oi-Lin Ng; John Wong
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

4.  Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy.

Authors:  I Ikai; Y Yamaoka; Y Yamamoto; N Ozaki; Y Sakai; S Satoh; N Shinkura; M Yamamoto
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

5.  Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma.

Authors:  Yonson Ku; Takeshi Iwasaki; Masahiro Tominaga; Takumi Fukumoto; Tetsuya Takahashi; Masahiro Kido; Satoshi Ogata; Masanori Takahashi; Yoshikazu Kuroda; Shinichi Matsumoto; Hidefumi Obara
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

6.  Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?

Authors:  Binkui Li; Yunfei Yuan; Guihua Chen; Liru He; Yaqi Zhang; Jinqing Li; Guohui Li; Wan Yee Lau
Journal:  BMC Cancer       Date:  2010-10-07       Impact factor: 4.430

7.  Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis.

Authors:  Keisuke Arai; Takumi Fukumoto; Masahiro Kido; Motofumi Tanaka; Kaori Kuramitsu; Hisoka Kinoshita; Shohei Komatsu; Daisuke Tsugawa; Sachio Terai; Taku Matsumoto; Tadahiro Goto; Sadaki Asari; Hirochika Toyama; Tetsuo Ajiki; Yonson Ku
Journal:  Surg Today       Date:  2016-07-27       Impact factor: 2.549

8.  New indication for reduction surgery in patients with advanced hepatocellular carcinoma with major vascular involvement.

Authors:  Naoto Gotohda; Taira Kinoshita; Masaru Konishi; Toshio Nakagohri; Shinichiro Takahashi; Junji Furuse; Hiroshi Ishii; Masahiro Yoshino
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

9.  Pathological complete response after percutaneous isolated hepatic perfusion in hepatocellular carcinoma with portal vein tumor thrombosis: a case report.

Authors:  Keisuke Arai; Takumi Fukumoto; Motofumi Tanaka; Kaori Kuramitsu; Masahiro Kido; Hisoka Kinoshita; Taku Matsumoto; Hirochika Toyama; Sadaki Asari; Tadahiro Goto; Tetsuo Ajiki; Yonson Ku
Journal:  Surg Case Rep       Date:  2016-05-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.